Zymeworks to Acquire Theravance Biopharma for $17 Per Share in Cash Plus CVR
The deal adds YUPELRI to Zymeworks’ portfolio.
/ 2 items
The deal adds YUPELRI to Zymeworks’ portfolio.
Theravance Biopharma's ampreloxetine failed its Phase 3 CYPRESS study for nOH in MSA. Company winds down program, cuts costs ~60%, focuses on YUPELRi cash flow, and speeds up strategic alternatives review to maximize shareholder value.